Researcher
Peter MESSIAEN
- Keywords:Biomedical sciences (incl. biochemistry)
- Disciplines:Immunology not elsewhere classified
Affiliations
- Immunology & Infection (Department)
Member
From1 Jan 2020 → Today - Immunology & Infection (Research group)
Member
From1 Jan 2020 → Today - Limburg Clinical Research Center (Research Center)
Member
From1 Jan 2020 → Today - Faculty of Medicine and Life Sciences (Faculty)
Member
From1 Feb 2015 → Today - Biomedical Research Institute (Research institute)
Member
From16 Nov 2018 → 31 Dec 2019 - Physiology - Biochemistry - Immunology (Department)
Member
From1 Feb 2015 → 31 Dec 2019 - Immunology - Biochemistry (Research group)
Member
From1 Feb 2015 → 31 Dec 2019
Projects
1 - 1 of 1
- Protective versus damaging aspects of the immune reaction in relation to clinical outcome in the Limburg COVID-19 cohortFrom15 Jun 2020 → 14 Jun 2022Funding: BOF - projects
Publications
1 - 10 of 42
- Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial(2023)
Authors: Tahilin Sanchez Karver, Miguel Pascual-Bernaldez, Alessandro Berni, Ahmed Hnoosh, Antonella Castagna, Peter MESSIAEN, Maria Jose Galindo Puerto, Mark Bloch, Eisuke Adachi, Gary Sinclair, et al.
Pages: 53 - 59 - Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium(2023)
Authors: Rakan Nasreddine, Eric Florence, Jean Cyr Yombi, Sophie Henrard, Gilles Darcis, Jens Van Praet, Linos D. Vandekerckhove, Sabine Allard, Remy Demeester, Peter MESSIAEN, et al.
Pages: 914 - 924 - Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium(2023)
Authors: Rakan Nasreddine, Jean Cyr Yombi, Gilles Darcis, Eric Florence, Sabine D. Allard, Marie-Angelique De Scheerder, Sophie Henrard, Remy Demeester, Peter MESSIAEN, Nathalie Ausselet, et al.
Pages: 267 - 278 - Virulence Factor Genes in Invasive Escherichia coli Are Associated with Clinical Outcomes and Disease Severity in Patients with Sepsis: A Prospective Observational Cohort Study(2023)
Authors: Valentino D'ONOFRIO, Reinoud Cartuyvels, Peter MESSIAEN, Ivan Barisic, Inge GYSSENS
- Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021(2023)
Authors: Jens T. Van Praet, Ben Serrien, Nathalie Ausselet, Gilles Darcis, Remy Demeester, Paul De Munter, Marie-Angelique De Scheerder, Jean-Christophe Goffard, Agnes Libois, Peter MESSIAEN, et al.
Pages: E4 - E6 - Continuum of HIV care by key populations in Belgium: Cross-sectional and longitudinal views(2023)
Authors: D. Van Beckhoven, B. Serrien, G. Darcis, R. Demeester, P. De Munter, S. Henrard, A. Libois, Peter MESSIAEN, J. Van Praet, J. Macq
Pages: 224 - 226 - Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort(2023)
Authors: Pieter RUYTINX, Patrick VANDORMAEL, Judith FRAUSSEN, Zoe PIETERS, Stef Thonissen, Niels HELLINGS, Piet STINISSEN, Ina CALLEBAUT, Joris PENDERS, Karolien VANHOVE, et al.
- Subjective sleep quality evolution in patients starting or switching to dolutegravir or cabotegravir: A real-world longitudinal study(2023)
Authors: Peter MESSIAEN, E. Van Steenkiste, J. Reumers, Janneke COX, K. van Halem, Jeroen VAN DER HILST
Pages: 591 - 592 - SOLAR 12-month European results: Randomized switch trial of CAB plus RPV vs. oral BIC/FTC/TAF(2023)
Authors: I. De Los Santos Gil, A. Ustianowski, G. Orofino, S. Scholten, Peter MESSIAEN, F. Maggiolo, D. Braun, C. Wyen, R. Demeester, C. Jacomet, et al.
Pages: 204 - 206 - Mental health impact of COVID-19 in frontline healthcare workers in a Belgian Tertiary care hospital: a prospective longitudinal study(2022)
Authors: Shauni Gilis, Peter MESSIAEN, Jessie Schoofs, Eveline Van Steenkiste
Pages: 533 - 540